Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With
177Lu-DOTATATE
PRRT
dosimetry
metastatic cardiac paraganglioma
personalized activity
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
05
2021
accepted:
08
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
12
2
2022
Statut:
epublish
Résumé
Primary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible. Available therapeutic modalities for metastatic disease include external beam radiation therapy as well as systemic treatments, namely A 47-year-old man with no medical history consulted for rapidly decreasing exercise tolerance. The investigation demonstrated an unresectable progressing metastatic cardiac paraganglioma with intracardiac extension. The patient was treated with personalized PRRT with
Identifiants
pubmed: 34367072
doi: 10.3389/fendo.2021.705271
pmc: PMC8339957
doi:
Substances chimiques
Organometallic Compounds
0
Radiopharmaceuticals
0
lutetium Lu 177 dotatate
AE221IM3BB
Octreotide
RWM8CCW8GP
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
705271Informations de copyright
Copyright © 2021 Huot Daneault, Desaulniers, Beauregard, Beaulieu, Arsenault, April, Turcotte and Buteau.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancers (Basel). 2019 Jun 28;11(7):
pubmed: 31261748
Clin Endocrinol (Oxf). 2019 Dec;91(6):718-727
pubmed: 31569282
Curr Oncol. 2020 Dec 21;28(1):115-127
pubmed: 33622997
J Thorac Cardiovasc Surg. 2006 Sep;132(3):705-6
pubmed: 16935141
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1490-1500
pubmed: 28361189
Ann Nucl Med. 2021 Jan;35(1):92-101
pubmed: 33135123
Int J Cardiol. 2013 Jun 20;166(2):315-20
pubmed: 22652039
Am J Emerg Med. 2015 Oct;33(10):1545.e3-6
pubmed: 26283614
CMAJ. 2017 Jul 31;189(30):E996
pubmed: 28760837
Clin Endocrinol (Oxf). 2014 Apr;80(4):487-501
pubmed: 24118038
EJNMMI Phys. 2018 Oct 15;5(1):25
pubmed: 30318563
Neuroendocrinology. 2019;109(4):287-298
pubmed: 30856620
J Clin Med. 2020 Jul 12;9(7):
pubmed: 32664679
Eur J Endocrinol. 2008 Mar;158(3):423-9
pubmed: 18299478
Clin Cancer Res. 2021 Jun 1;27(11):2989-2995
pubmed: 33685867
Endocr Rev. 1994 Jun;15(3):356-68
pubmed: 8076587
Clin Endocrinol (Oxf). 2014 Nov;81(5):642-51
pubmed: 25041164
Ann Thorac Surg. 2012 Jun;93(6):1972-6
pubmed: 22537533
Surg Oncol Clin N Am. 2016 Jan;25(1):119-38
pubmed: 26610778
Ann Surg. 1999 Jun;229(6):755-64; discussion 764-6
pubmed: 10363888
J Nucl Med. 2019 May;60(5):623-630
pubmed: 30291194
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709